Clinical trial · Observational
Iodinated Contrast Media Induced Hyperthyroidism
Prevention of Iodinated Contrast Media Induced Hyperthyroidism in Patients With Euthyroid Goiter
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The proper synthesis of thyroid hormones is dependent on adequate iodine supply. The mean daily iodine intake recommended by World Health Organization is 150 mg. Iodinated contrast medium (ICM) typically contains 13 500 mg of free iodine and 15-60 g of bound iodine, an amount well above acceptable upper level. In a situation of excess iodine, thyroid discontinues the release of hormones (Wolff-Chaikoff effect), which is usually transient, although can persist causing hypothyroidism. Iodine-induced hyperthyroidism (IIH), known as the Jod-Basedow phenomenon is infrequent, but elderly patients and individuals with autonomously functioning nodular goiters are at higher risk of developing this dysfunction. According to recent studies the risk of ICM-induced hyperthyroidism appears to be low. The prevalence has not been well assessed and varies from 1 % to 10 %. Currently, there are no specific guidelines concerning the prophylactic therapy of IIH. American Thyroid Association (ATA) does not recommend routine administration of antithyroid drugs before iodinated contrast medium for all patients, however, advises to consider prophylaxis in patients at high risk of developing IIH or with cardiovascular comorbidities. ATA recommends avoidance of additional iodine and administration of b-blockers alone or with antithyroid drugs as a treatment of IIH, depending on the severity of hyperthyroidism. This study was performed to evaluate the influence of ICM on thyroid status and advantages of prophylactic therapy during ICM exposure in patients with euthyroid goiter and cardiovascular comorbidities. The association between the incidence of IIH and thyroid volume was also assessed.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Contrast Media Adverse Reaction | — | UNRESOLVED | — |
| Hyperthyroidism; Goiter | — | UNRESOLVED | — |
| Hyperthyroidism/Thyrotoxicosis | — | UNRESOLVED | — |
| Iodine Induced Thyrotoxicosis | — | UNRESOLVED | — |
| Thyrotoxicosis of Other Specified Origin | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Administration of iodinated contrast media | Procedure | — | UNRESOLVED |
| Prophylactic administration of antithyroid drugs before iodinated contrast media exposure | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Group with prophylaxis
- description
- Group of 13 patients with euthyroid goiter who received prophylactic treatment before and after iodinated contrast medium (ICM) injection. 6 patients received thiamazole with sodium perchlorate, one day prior to ICM and for at least 14 days after for thiamazole (20-40 mg/daily) and 10 days after for sodium perchlorate (900 mg/daily). 7 patients received only thiamazole as prophylactic treatment due to lack of sodium perchlorate at the time.
- interventionNames
- Procedure: Administration of iodinated contrast media
- Drug: Prophylactic administration of antithyroid drugs before iodinated contrast media exposure
- label
- Group without prophylaxis
- description
- Group of 23 patients with euthyroid goiter who received no prophylactic treatment before iodinated contrast medium injection.
- interventionNames
- Procedure: Administration of iodinated contrast media
Primary outcomes (3)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * euthyroidism at baseline (defined as TSH level within the reference range) * diffuse or multinodular goiter * iodinated contrast media (ICM) exposure * time of observation after ICM exposure longer than 4 weeks Exclusion Criteria: * Graves' disease * administration of thyroid hormones, glucocorticoids, iodine-containing medications or iodine contrast agent within the past 6 months
References
Publications (0)
Data not yet available